Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 -deficient mouse embryonic fibroblasts
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
A mismatch between metabolic demand and oxygen delivery leads to microenvironmental changes in solid tumors. The resulting tumor hypoxia is associated with malignant progression, therapy resistance and poor prognosis. However, the molecular mechanisms underlying therapy resistance in hypoxic tumors are not fully understood. The hypoxia-inducible factor (HIF) is a master transcriptional activator of oxygen-regulated gene expression. Transformed mouse embryonic fibroblasts (MEFs) derived from HIF-1alpha-deficient mice are a popular model to study HIF function in tumor progression. We previously found increased chemotherapy and irradiation susceptibility in the absence of HIF-1alpha. Here, we show by single-cell electrophoresis, histone 2AX phosphorylation and nuclear foci formation of gammaH2AX and 53BP1, that the number of DNA double-strand breaks (DSB) is increased in untreated and etoposide-treated HIF-deficient MEFs. In etoposide-treated cells, cell cycle control and p53-dependent gene expression were not affected by the absence of HIF-1alpha. Using a candidate gene approach to screen 17 genes involved in DNA repair, messenger RNA (mRNA) and protein of three members of the DNA-dependent protein kinase complex were found to be decreased in HIF-deficient MEFs. Of note, residual HIF-1alpha protein in cancer cells with a partial HIF-1alpha mRNA knockdown was sufficient to confer chemoresistance. In summary, these data establish a novel molecular link between HIF and DNA DSB repair. We suggest that selection of early, non-hypoxic tumor cells expressing low levels of HIF-1alpha might contribute to HIF-dependent tumor therapy resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · cited 1×
“Central to the physiological response to hypoxia is the oxygenlabile a subunit of the hypoxia-inducible factor (HIF)-1 (4, 5 ).”
BackgroundHypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
Wenger, R. H. (2002) · The FASEB Journal · doi:10.1096/fj.01-0944rev · Cited by 1,135 · cited 1×
“Central to the physiological response to hypoxia is the oxygenlabile a subunit of the hypoxia-inducible factor (HIF)-1 ( 4 ,5).”
BackgroundSelf-citationRegulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967
Loss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840
Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH
Švastová, E., Hulı́ková, A., Rafajová, M., Zat'ovičová, M., Gibadulinová, A., Casini, A., Cecchi, A., Scozzafava, A., Supuran, C. T., Pastorek, J., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.10.043 · Cited by 711
Erler, J. T., Cawthorne, C. J., Williams, K. J., Koritzinsky, M., Wouters, B. G., Wilson, C., Miller, C., Demonacos, C., Stratford, I. J., & Dive, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2875-2889.2004 · Cited by 400
Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203938 · Cited by 396
Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity
Moeller, B. J., Dreher, M. R., Rabbani, Z. N., Schroeder, T., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.016 · Cited by 374
Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, C., Turley, H., Talks, K., Gatter, K. C., & Harris, A. L. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02848-1 · Cited by 361
The hypoxia-inducible factor-1α is a negative factor for tumor therapy
Unruh, A., Ressel, A., Mohamed, H. G., Johnson, R. S., Nadrowitz, R., Richter, E., Katschinski, D. M., & Wenger, R. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206385 · Cited by 334 · cited 7×
“Etoposide induces cell cycle arrest in MEFs irrespective of the presence of HIF-1a We had shown previously that chemosensitivity and radiosensitivity are increased in HIF-1a-deficient MEFs ( 29 ).”
BackgroundMethodResultSelf-citationWartenberg, M., Ling, F. C., Müschen, M., Klein, F., Acker, H., Gassmann, M., Petrat, K., Pütz, V., Hescheler, J., & Sauer, H. (2003) · The FASEB Journal · doi:10.1096/fj.02-0358fje · Cited by 287
Martinive, P., Defresne, F., Bouzin, C., Saliez, J., Lair, F., Grégoire, V., Michiels, C., Dessy, C., & Feron, O. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2056 · Cited by 190 · cited 1×
“On the other hand, experimentally increasing HIF-1a enhanced therapy resistance ( 38 ,39).”
BackgroundBrown, L. M., Cowen, R. L., Debray, C., Eustace, A., Erler, J. T., Sheppard, F. C., Parker, C. A., Stratford, I. J., & Williams, K. J. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.015743 · Cited by 125
Zhang, X., Kon, T., Wang, H., Li, F., Huang, Q., Rabbani, Z. N., Kirkpatrick, J. P., Vujaskovic, Z., Dewhirst, M. W., & Li, C.-Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2301 · Cited by 120
Cited by
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
“For example, the E3 ubiquitin ligase Smurf1 determines cell apoptosis rates downstream of DNA damage–induced ATR–Chk1 signaling by promoting the death of transformed cells [107, 108].”
BackgroundHypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 608
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Cancer Stem Cells and Drug Resistance: The Potential of Nanomedicine
Vinogradov, S., & Wei, X. (2012) · Nanomedicine · doi:10.2217/nnm.12.22 · Cited by 474
Metadata
- Authors
- Wirthner, R., Wrann, S., Balamurugan, K., Wenger, R. H., & Stiehl, D. P.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-08-19
- Volume
- 29
- Issue
- 12
- Pages
- 2306-2316
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2154060890
- Cited by
- 51
- References
- 16
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.